Last-Resort drug made available for stubborn lung infections
NCT ID NCT04334070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides Lamprene (clofazimine), a drug normally used for leprosy, to adults with NTM infections that haven't responded to other treatments or caused intolerable side effects. Patients take 100 mg of clofazimine daily as part of a multi-drug regimen. The goal is to offer a potential option when no standard therapies are left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Clofazimine (Lamprene), a drug taken as 100 mg capsules daily with food, as part of a multi-drug regimen
- What this could lead to
- If this program helps, it could offer a treatment option for people with hard-to-treat NTM infections who have run out of other choices.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are not systematically collected. Clofazimine is not FDA-approved for NTM, and its effectiveness and safety for this use are not fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.